Research and Development Expenses Breakdown: Regeneron Pharmaceuticals, Inc. vs Alnylam Pharmaceuticals, Inc.

Biotech Giants' R&D Spending: A Decade of Growth

__timestampAlnylam Pharmaceuticals, Inc.Regeneron Pharmaceuticals, Inc.
Wednesday, January 1, 20141902490001271353000
Thursday, January 1, 20152764950001620577000
Friday, January 1, 20163823920002052295000
Sunday, January 1, 20173906350002075142000
Monday, January 1, 20185054200002186100000
Tuesday, January 1, 20196551140003036600000
Wednesday, January 1, 20206548190002735000000
Friday, January 1, 20217921560002908100000
Saturday, January 1, 20228830150003592500000
Sunday, January 1, 202310044150004439000000
Monday, January 1, 202411262320005132000000
Loading chart...

Unleashing the power of data

A Decade of Innovation: R&D Spending in Biotech

In the competitive world of biotechnology, research and development (R&D) spending is a key indicator of a company's commitment to innovation. Over the past decade, Regeneron Pharmaceuticals, Inc. and Alnylam Pharmaceuticals, Inc. have demonstrated significant investment in R&D, reflecting their dedication to advancing medical science.

Regeneron Pharmaceuticals, Inc.

Regeneron has consistently outpaced Alnylam in R&D expenditure, with a remarkable 250% increase from 2014 to 2023. By 2023, their R&D spending reached nearly $4.44 billion, underscoring their leadership in the biotech sector.

Alnylam Pharmaceuticals, Inc.

Alnylam, while smaller in scale, has shown impressive growth, with R&D expenses rising by over 400% during the same period. Their 2023 expenditure of approximately $1 billion highlights their strategic focus on pioneering RNA interference therapeutics.

This data not only showcases the financial commitment of these companies but also their pivotal role in driving innovation in the pharmaceutical industry.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025